TY - JOUR
T1 - Novel Markers for Liquid Biopsies in Cancer Management
T2 - Circulating Platelets and Extracellular Vesicles
AU - Corvigno, Sara
AU - Johnson, Anna Maria
AU - Wong, Kwong Kwok
AU - Cho, Min Soon
AU - Afshar-Kharghan, Vahid
AU - Menter, David G.
AU - Sood, Anil K.
N1 - Publisher Copyright:
© 2022 American Association for Cancer Research.
PY - 2022/7
Y1 - 2022/7
N2 - Although radiologic imaging and histologic assessment of tumor tissues are classic approaches for diagnosis and monitoring of treatment response, they have many limitations. These include challenges in distinguishing benign from malignant masses, difficult access to the tumor, high cost of the procedures, and tumor heterogeneity. In this setting, liquid biopsy has emerged as a potential alternative for both diagnostic and monitoring purposes. The approaches to liquid biopsy include cell-free DNA/circulating tumor DNA, long and micro noncoding RNAs, proteins/peptides, carbohydrates/lectins, lipids, and metabolites. Other approaches include detection and analysis of circulating tumor cells, extracellular vesicles, and tumor-activated platelets. Ultimately, reliable use of liquid biopsies requires bioinformatics and statistical integration of multiple datasets to achieve approval in a Clinical Laboratory Improvement Amendments setting. This review provides a balanced and critical assessment of recent discoveries regarding tumorderived biomarkers in liquid biopsies along with the potential and pitfalls for cancer detection and longitudinal monitoring.
AB - Although radiologic imaging and histologic assessment of tumor tissues are classic approaches for diagnosis and monitoring of treatment response, they have many limitations. These include challenges in distinguishing benign from malignant masses, difficult access to the tumor, high cost of the procedures, and tumor heterogeneity. In this setting, liquid biopsy has emerged as a potential alternative for both diagnostic and monitoring purposes. The approaches to liquid biopsy include cell-free DNA/circulating tumor DNA, long and micro noncoding RNAs, proteins/peptides, carbohydrates/lectins, lipids, and metabolites. Other approaches include detection and analysis of circulating tumor cells, extracellular vesicles, and tumor-activated platelets. Ultimately, reliable use of liquid biopsies requires bioinformatics and statistical integration of multiple datasets to achieve approval in a Clinical Laboratory Improvement Amendments setting. This review provides a balanced and critical assessment of recent discoveries regarding tumorderived biomarkers in liquid biopsies along with the potential and pitfalls for cancer detection and longitudinal monitoring.
UR - http://www.scopus.com/inward/record.url?scp=85134360289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134360289&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-22-0087
DO - 10.1158/1535-7163.MCT-22-0087
M3 - Review article
C2 - 35545008
AN - SCOPUS:85134360289
SN - 1535-7163
VL - 21
SP - 1067
EP - 1075
JO - Molecular cancer therapeutics
JF - Molecular cancer therapeutics
IS - 7
ER -